Microarray analyses of genes differentially expressed by diet (Black Beans and Soy Flour) during azoxymethane-induced colon carcinogenesis in rats

Journal of Nutrition and Metabolism

Volumn 2012, Issue , 2012, Pages

  Rondini, Elizabeth A ^a   Bennink, Maurice R ^a  

^a Michigan State University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84887246558     PISSN: 20900724     EISSN: 20900732     Source Type: Journal    
DOI: 10.1155/2012/351796     Document Type: Article

References (149)

1. J. Ferlay, H. Shin, F. Bray et al., "GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide. IARC CancerBase No. 10 [Internet]," Lyon, France, 2010.
2. B. Armstrong and R. Doll, "Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices," International Journal of Cancer, vol. 15, no. 4, pp. 617-631, 1975.
3. R. Doll and R. Peto, "The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today," Journal of the National Cancer Institute, vol. 66, no. 6, pp. 1191-1308, 1981.
4. WCRF and AICR, Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective, World Cancer Research Fund and American Institute for Cancer Research, Washington, DC, USA, 2007.
5. J. D. Potter, "Colorectal cancer: molecules and populations," Journal of the National Cancer Institute, vol. 91, no. 11, pp. 916-932, 1999.
6. K. A. Steinmetz and J. D. Potter, "Food-group consumption and colon cancer in the Adelaide case-control study. I. Vegetables and fruit," International Journal of Cancer, vol. 53, no. 5, pp. 711-719, 1993.
7. G. E. Fraser, "Associations between diet and cancer, ischemic heart disease, and all- cause mortality in non-Hispanic white California Seventh-day Adventists," American Journal of Clinical Nutrition, vol. 70, no. 3, 1999.
8. P. N. Singh and G. E. Fraser, "Dietary risk factors for colon cancer in a low-risk population," American Journal of Epidemiology, vol. 148, no. 8, pp. 761-774, 1998.
9. L. L.Marchand, J. H. Hankin, L. R.Wilkens, L. N. Kolonel, H. N. Englyst, and L. C. Lyu, "Dietary fiber and colorectal cancer risk," Epidemiology, vol. 8, no. 6, pp. 658-665, 1997.
10. H. Deneo-Pellegrini, P. Boffetta, E. De Stefani, A. Ronco, P. Brennan, andM. Mendilaharsu, "Plant foods and differences between colon and rectal cancers," European Journal of Cancer Prevention, vol. 11, no. 4, pp. 369-375, 2002.
11. E. Lanza, T. J. Hartman, P. S. Albert et al., "High dry bean intake and reduced risk of advanced colorectal adenoma recurrence among participants in the polyp prevention trial," Journal of Nutrition, vol. 136, no. 7, pp. 1896-1903, 2006.
12. J. S. Witte, M. P. Longnecker, C. L. Bird, E. R. Lee, H. D. Frankl, and R. W. Haile, "Relation of vegetable, fruit, and grain consumption to colorectal adenomatous polyps," American Journal of Epidemiology, vol. 144, no. 11, pp. 1015- 1025, 1996.
13. P. Correa, "Epidemiological correlations between diet and cancer frequency," Cancer Research, vol. 41, no. 9, pp. 3685- 3690, 1981.
14. R. F. Jacoby, X. Llor, B. B. Teng, N. O. Davidson, and T. A. Brasitus, "Mutations in the K-ras oncogene induced by 1,2-dimethylhydrazine in preneoplastic and neoplastic rat colonic mucosa," Journal of Clinical Investigation, vol. 87, no. 2, pp. 624-630, 1991.
15. A. A. Vivona, B. Shpitz, A.Medline et al., "K-rasmutations in aberrant crypt foci, adenomas and adenocarcinomas during azoxymethane-induced colon carcinogenesis," Carcinogenesis, vol. 14, no. 9, pp. 1777-1781, 1993.
16. S. E. Pories, N. Ramchurren, I. Summerhayes, and G. Steele, "Animal models for colon carcinogenesis," Archives of Surgery, vol. 128, no. 6, pp. 647-653, 1993.
17. M. Takahashi, K. Fukuda, T. Sugimura, and K. Wakabayashi, "β-catenin is frequently mutated and demonstrates altered cellular location in azoxymethane-induced rat colon tumors," Cancer Research, vol. 58, no. 1, pp. 42-46, 1998.
18. M. Perse and A. Cerar, "Morphological and molecular alterations in 1,2 dimethylhydrazine and azoxymethane induced colon carcinogenesis in rats," Journal of Biomedicine and Biotechnology, vol. 2011, Article ID 473964, 2011.
19. J. Chen and X. F. Huang, "The signal pathways in azoxymethane- induced colon cancer and preventive implications," Cancer Biology and Therapy, vol. 8, no. 14, pp. 1313-1317, 2009.
20. C. De Filippo, G. Caderni, M. Bazzicalupo et al., "Mutations of the Apc gene in experimental colorectal carcinogenesis induced by azoxymethane in F344 rats," British Journal of Cancer, vol. 77, no. 12, pp. 2148-2151, 1998.
21. M. Takahashi, M. Mutoh, T. Kawamori, T. Sugimura, and K. Wakabayashi, "Altered expression of β-catenin, inducible nitric oxide synthase and cyclooxygenase-2 in azoxymethaneinduced rat colon carcinogenesis," Carcinogenesis, vol. 21, no. 7, pp. 1319-1327, 2000.
22. Y. Yamada, N. Yoshimi, Y. Hirose et al., "Frequent β-catenin gene mutations and accumulations of the protein in the putative preneoplastic lesions lacking macroscopic aberrant crypt foci appearance, in rat colon carcinogenesis," Cancer Research, vol. 60, no. 13, pp. 3323-3327, 2000.
23. M. Takahashi, S. Nakatsugi, T. Sugimura, and K. Wakabayashi, "Frequent mutations of the β-catenin gene in mouse colon tumors induced by azoxymethane," Carcinogenesis, vol. 21, no. 6, pp. 1117-1120, 2000.
24. R. N. DuBois, A. Radhika, B. S. Reddy, and A. J. Entingh, "Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors," Gastroenterology, vol. 110, no. 4, pp. 1259- 1262, 1996.
25. T. Ohta, M. Takahashi, and A. Ochiai, "Increased protein expression of both inducible nitric oxide synthase and cyclooxygenase-2 in human colon cancers," Cancer Letters, vol. 239, no. 2, pp. 246-253, 2006.
26. K. Watanabe, T. Kawamori, S. Nakatsugi, and K. Wakabayashi, "Cox-2 and inos, good targets for chemoprevention of colon cancer," BioFactors, vol. 12, no. 1-4, pp. 129-133, 2000.
27. K. Guda, C. Giardina, P. Nambiar, H. Cui, and D. W. Rosenberg, "Aberrant transforming growth factor-β signaling in azoxymethane-induced mouse colon tumors," Molecular Carcinogenesis, vol. 31, no. 4, pp. 204-213, 2001.
28. J. Shao, H. Sheng, R. Aramandla et al., "Coordinate regulation of cyclooxygenase-2 and TGF-β1 in replication errorpositive colon cancer and azoxymethane-induced rat colonic tumors," Carcinogenesis, vol. 20, no. 2, pp. 185-191, 1999.
29. N. Bellam and B. Pasche, "Tgf-beta signaling alterations and colon cancer," Cancer Treatment and Research, vol. 155, pp. 85-103, 2010.
30. M. R. Bennink and A. S. Om, "Inhibition of Colon Cancer (CC) by soy phytochemicals but not by soy protein," The FASEB Journal, vol. 12, no. 5, p. A655, 1998.
31. M. R. Bennink, A. S. Om, and Y.Miyagi, "Inhibition of colon cancer (CC) by soy flour but not by genistin or a mixture of isoflavones," The FASEB Journal, vol. 13, p. A50, 1999.
32. L. Hangen andM. R. Bennink, "Consumption of black beans and navy beans (Phaseolus vulgaris) reduced azoxymethaneinduced colon cancer in rats," Nutrition and Cancer, vol. 44, no. 1, pp. 60-65, 2002.
33. E. A. Rondini and M. R. Bennink, "Defatted soy flour, but not soy concentrate, reduces azoxymethane-induced colon carcinogenesis," Journal of Nutrition, vol. 132, p. 589S, 2002.
34. R. Hakkak, S. Korourian,M. J. J. Ronis, J.M. Johnston, and T. M. Badger, "Soy protein isolate consumption protects against azoxymethane-induced colon tumors in male rats," Cancer Letters, vol. 166, no. 1, pp. 27-32, 2001.
35. J. S. Hughes, C. Ganthavorn, and S. Wilson-Sanders, "Dry beans inhibit azoxymethane-induced colon carcinogenesis in F344 rats," Journal of Nutrition, vol. 127, no. 12, pp. 2328- 2333, 1997.
36. G. Bobe, K. G. Barrett, R. A.Mentor-Marcel et al., "Dietary cooked navy beans and their fractions attenuate colon carcinogenesis in azoxymethane-induced Ob/Ob mice," Nutrition and Cancer, vol. 60, no. 3, pp. 373-381, 2008.
37. T. Liu, A. O. Mokuolu, C. V. Rao, B. S. Reddy, and P. R. Holt, "Regional chemoprevention of carcinogen-induced tumors in rat colon," Gastroenterology, vol. 109, no. 4, pp. 1167-1172, 1995.
38. P. G. Reeves, F. H. Nielsen, and G. C. Fahey, "AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet," Journal of Nutrition, vol. 123, no. 11, pp. 1939-1951, 1993.
39. D.W.Huang, B. T. Sherman, and R. A. Lempicki, "Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources," Nature Protocols, vol. 4, no. 1, pp. 44-57, 2009.
40. D. W. Huang, B. T. Sherman, and R. A. Lempicki, "Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists," Nucleic Acids Research, vol. 37, no. 1, pp. 1-13, 2009.
41. K. Fujiwara, M. Ochiai, T. Ohta et al., "Global gene expression analysis of rat colon cancers induced by a food-borne carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine," Carcinogenesis, vol. 25, no. 8, pp. 1495-1505, 2004.
42. I. C. Lawrance, C. Fiocchi, and S. Chakravarti, "Ulcerative colitis and Crohns disease: distinctive gene expression profiles and novel susceptibility candidate genes," Human Molecular Genetics, vol. 10, no. 5, pp. 445-456, 2001.
43. M. R. Bennink, "Dietary soy reduces colon carcinogenesis in human and rats: soy and colon cancer," Advances in Experimental Medicine and Biology, vol. 492, pp. 11-17, 2001.
44. R. Nagashima, K.Maeda, Y. Imai, and T. Takahashi, "Lamina propria macrophages in the human gastrointestinal mucosa: their distribution, immunohistological phenotype, and function," Journal of Histochemistry and Cytochemistry, vol. 44, no. 7, pp. 721-731, 1996.
45. I.Maric, P.G.Holt, M. H. Perdue, and J. Bienenstock, "Class IIMHC antigen (Ia)-bearing dendritic cells in the epithelium of the rat intestine," Journal of Immunology, vol. 156, no. 4, pp. 1408-1414, 1996.
46. D. C. Baumgart and S. R. Carding, "Inflammatory bowel disease: cause and immunobiology," The Lancet, vol. 369, no. 9573, pp. 1627-1640, 2007.
47. A. M. Mowat and J. L. Viney, "The anatomical basis of intestinal immunity," Immunological Reviews, vol. 156, pp. 145-166, 1997.
48. H. Tlaskalova-Hogenova, M. A. Farre-Castany, R. Stepankov a et al., "The gut as a lymphoepithelial organ: the role of intestinal epithelial cells in mucosal immunity," Folia Microbiologica, vol. 40, no. 4, pp. 385-391, 1995.
49. H. Lue, M. Thiele, J. Franz et al., "Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity," Oncogene, vol. 26, no. 35, pp. 5046- 5059, 2007.
50. L. Leng, C. N. Metz, Y. Fang et al., "MIF signal transduction initiated by binding to CD74," Journal of Experimental Medicine, vol. 197, no. 11, pp. 1467-1476, 2003.
51. E. E. Deschner and M. Lipkin, "Study of human rectal epithelial cells in vitro. III. RNA, protein, and DNA synthesis in polyps and adjacent mucosa," Journal of the National Cancer Institute, vol. 44, no. 1, pp. 175-185, 1970.
52. K. Fujiwara,M. Ochiai, T. Ubagai et al., "Differential gene expression profiles in colon epithelium of two rat strains with distinct susceptibility to colon carcinogenesis after exposure to PhIP in combinationwith dietary high fat," Cancer Science, vol. 94, no. 8, pp. 672-678, 2003.
53. H. M. Lee, G. H. Greeley, and E. W. Englander, "Ageassociated changes in gene expression patterns in the duodenum and colon of rats," Mechanisms of Ageing and Development, vol. 122, no. 4, pp. 355-371, 2001.
54. N. Khansari, Y. Shakiba, and M. Mahmoudi, "Chronic inflammation and oxidative stress as a major cause of agerelated diseases and cancer," Recent Patents on Inflammation and Allergy Drug Discovery, vol. 3, no. 1, pp. 73-80, 2009.
55. A. Federico, F. Morgillo, C. Tuccillo, F. Ciardiello, and C. Loguercio, "Chronic inflammation and oxidative stress in human carcinogenesis," International Journal of Cancer, vol. 121, no. 11, pp. 2381-2386, 2007.
56. M. Macarthur, G. L. Hold, and E. M. El-Omar, "Inflammation and Cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy," American Journal of Physiology, vol. 286, no. 4, pp. G515-G520, 2004.
57. C. J. Van Der Woude, J. H. Kleibeuker, P. L. M. Jansen, and H. Moshage, "Chronic inflammation, apoptosis and (pre- )malignant lesions in the gastro-intestinal tract," Apoptosis, vol. 9, no. 2, pp. 123-130, 2004.
58. E. Shacter and S. A. Weitzman, "Chronic inflammation and cancer," Oncology, vol. 16, no. 2, pp. 217-230, 2002.
59. H. Bartsch and J. Nair, "Chronic inflammation and oxidative stress in the genesis and perpetuation of cancer: role of lipid peroxidation, DNA damage, and repair," Langenbecks Archives of Surgery, vol. 391, no. 5, pp. 499-510, 2006.
60. M. B. Grisham, D. Jourdheuil, and D. A. Wink, "Chronic inflammation and reactive oxygen and nitrogen metabolism- implications in DNA damage and mutagenesis," Alimentary Pharmacology and Therapeutics, vol. 14, supplement 1, pp. 3-9, 2000.
61. D. K. Podolsky, "Mucosal immunity and inflammation V. Innate mechanisms of mucosal defense and repair: the best offense is a good defense," American Journal of Physiology, vol. 277, no. 3, pp. G495-G499, 1999.
62. M. A. McGuckin, S. K. Linden, P. Sutton, and T. H. Florin, "Mucin dynamics and enteric pathogens," Nature Reviews Microbiology, vol. 9, no. 4, pp. 265-278, 2011.
63. J. R. Turner, "Molecular basis of epithelial barrier regulation: from basic mechanisms to clinical application," American Journal of Pathology, vol. 169, no. 6, pp. 1901-1909, 2006.
64. J. R. Turner, "Intestinal mucosal barrier function in health and disease," Nature Reviews Immunology, vol. 9, no. 11, pp. 799-809, 2009.
65. Y. Tang, D. R. Clayburgh, N. Mittal et al., "Epithelial NF- κB enhances transmucosal fluid movement by altering tight junction protein composition after T cell activation," American Journal of Pathology, vol. 176, no. 1, pp. 158-167, 2010.
66. J. Matricon, N. Barnich, and D. Ardid, "Immunopathogenesis of inflammatory bowel disease," Self/Nonself Immune Recognition and Signaling, vol. 1, no. 4, pp. 299-309, 2010.
67. S. Y. Salim and J. D. Soderholm, "Importance of disrupted intestinal barrier in inflammatory bowel diseases," Inflammatory Bowel Diseases, vol. 17, no. 1, pp. 362-381, 2011.
68. M. A. A. Schepens, A. J. Schonewille, C. Vink et al., "Supplemental calcium attenuates the colitis-related increase in diarrhea, intestinal permeability, and extracellular matrix breakdown inHLA-B27 transgenic rats," Journal of Nutrition, vol. 139, no. 8, pp. 1525-1533, 2009.
69. G. An, B.Wei, B. Xia et al., "Increased susceptibility to colitis and colorectal tumors in mice lacking core 3-derived Oglycans," Journal of Experimental Medicine, vol. 204, no. 6, pp. 1417-1429, 2007.
70. A. P. Soler, R. D. Miller, K. V. Laughlin, N. Z. Carp, D. M. Klurfeld, and J. M. Mullin, "Increased tight junctional permeability is associated with the development of colon cancer," Carcinogenesis, vol. 20, no. 8, pp. 1425-1431, 1999.
71. Y. Niv, "Mucin and colorectal cancer," Israel Medical Association Journal, vol. 2, no. 10, pp. 775-777, 2000.
72. Y. S. Kim, "Mucin glycoproteins in colonic neoplasia," Keio Journal of Medicine, vol. 47, no. 1, pp. 10-18, 1998.
73. M. Bruewer, S. Samarin, and A. Nusrat, "Inflammatory bowel disease and the apical junctional complex," Annals of the New York Academy of Sciences, vol. 1072, pp. 242-252, 2006.
74. F. Vaccina, F. Scorcioni, M. Pedroni et al., "Scanning electron microscopy of aberrant crypt foci in human colorectal mucosa,"Anticancer Research, vol. 18, no. 5 A, pp. 3451-3456, 1998.
75. S.Nittka, J.Gunther, C. Ebisch, A. Erbersdobler, andM.Neumaier, "The human tumor suppressor CEACAM1 modulates apoptosis and is implicated in early colorectal tumorigenesis," Oncogene, vol. 23, no. 58, pp. 9306-9313, 2004.
76. S. Nittka, C. Bohm, H. Zentgraf, and M. Neumaier, "The CEACAM1-mediated apoptosis pathway is activated by CEA and triggers dual cleavage of CEACAM1," Oncogene, vol. 27, no. 26, pp. 3721-3728, 2008.
77. L. Buscail, J. P. Esteve, N. Saint-Laurent et al., "Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms," Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 5, pp. 1580-1584, 1995.
78. L. Buscail, N. Saint-Laurent, E. Chastre et al., "Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer," Cancer Research, vol. 56, no. 8, pp. 1823-1827, 1996.
79. C. Casini Raggi, A. Calabro, D. Renzi et al., "Quantitative evaluation of somatostatin receptor subtype 2 expression in sporadic colorectal tumor and in the corresponding normal mucosa," Clinical Cancer Research, vol. 8, no. 2, pp. 419-427, 2002.
80. R. Xiao, T.M. Badger, and F. A. Simmen, "Dietary exposure to soy or whey proteins alters colonic global gene expression profiles during rat colon tumorigenesis," Molecular Cancer, vol. 4, article 1, 2005.
81. R. P. Bakshi, S. Galande, and K.Muniyappa, "Functional and regulatory characteristics of eukaryotic type II DNA topoisomerase," Critical Reviews in Biochemistry and Molecular Biology, vol. 36, no. 1, pp. 1-37, 2001.
82. B. M. Boman, R. Walters, J. Z. Fields et al., "Colonic crypt changes during adenoma development in familial adenomatous polyposis: immunohistochemical evidence for expansion of the crypt base cell population," American Journal of Pathology, vol. 165, no. 5, pp. 1489-1498, 2004.
83. M. Castedo, J. L. Perfettini, T. Roumier, and G. Kroemer, "Cyclin-dependent kinase-1: linking apoptosis to cell cycle and mitotic catastrophe," Cell Death and Differentiation, vol. 9, no. 12, pp. 1287-1293, 2002.
84. W. R. Taylor and G. R. Stark, "Regulation of the G2/M transition by p53," Oncogene, vol. 20, no. 15, pp. 1803-1815, 2001.
85. J. H. Cummings, "Short chain fatty acids in the human colon," Gut, vol. 22, no. 9, pp. 763-779, 1981.
86. J. H. Cummings and H. N. Englyst, "Fermentation in the human large intestine and the available substrates," American Journal of Clinical Nutrition, vol. 45, no. 5, pp. 1243-1255, 1987.
87. S. I. Cook and J. H. Sellin, "Review article: short chain fatty acids in health and disease," Alimentary Pharmacology and Therapeutics, vol. 12, no. 6, pp. 499-507, 1998.
88. S. J. Miller, "Cellular and physiological effects of short-chain fatty acids," Mini-Reviews in Medicinal Chemistry, vol. 4, no. 8, pp. 839-845, 2004.
89. A. Hague, A. M.Manning, K. A. Hanlon, L. I. Huschtscha, D. Hart, and C. Paraskeva, "Sodium butyrate induces apoptosis in human colonic tumour cell lines in a p53-independent pathway: implications for the possible role of dietary fibre in the prevention of large-bowel cancer," International Journal of Cancer, vol. 55, no. 3, pp. 498-505, 1993.
90. B. G. Heerdt, M. A. Houston, and L. H. Augenlicht, "Shortchain fatty acid-initiated cell cycle arrest and apoptosis of colonic epithelial cells is linked to mitochondrial function," Cell Growth and Differentiation, vol. 8, no. 5, pp. 523-532, 1997.
91. L.H. Augenlicht, G. M. Anthony, T. L. Church et al., "Shortchain fatty acid metabolism, apoptosis, and Apc-initiated tumorigenesis in the mouse gastrointestinalmucosa," Cancer Research, vol. 59, no. 23, pp. 6005-6009, 1999.
92. R. Thibault, F. Blachier, B. Darcy-Vrillon, P. De Coppet, A. Bourreille, and J. P. Segain, "Butyrate utilization by the colonic mucosa in inflammatory bowel diseases: a transport deficiency," Inflammatory Bowel Diseases, vol. 16, no. 4, pp. 684-695, 2010.
93. K. Birkenkamp-Demtroder, L. L. Christensen, S.H. Olesen et al., "Gene expression in colorectal cancer," Cancer Research, vol. 62, no. 15, pp. 4352-4363, 2002.
94. A. G. Buckland, E. L. Heeley, and D. C. Wilton, "Bacterial cell membrane hydrolysis by secreted phospholipases A2: a major physiological role of human group IIa sPLA2 involving both bacterial cell wall penetration and interfacial catalysis," Biochimica et Biophysica Acta, vol. 1484, no. 2-3, pp. 195-206, 2000.
95. A. G. Buckland and D. C. Wilton, "The antibacterial properties of secreted phospholipases A2," Biochimica et Biophysica Acta, vol. 1488, no. 1-2, pp. 71-82, 2000.
96. R. N. Cunliffe, "α-Defensins in the gastrointestinal tract," Molecular Immunology, vol. 40, no. 7, pp. 463-467, 2003.
97. R. N. Cunliffe and Y. R. Mahida, "Expression and regulation of antimicrobial peptides in the gastrointestinal tract," Journal of Leukocyte Biology, vol. 75, no. 1, pp. 49-58, 2004.
98. Y. R. Mahida and R. N. Cunliffe, "Defensins and mucosal protection," Novartis Foundation Symposium, vol. 263, pp. 71-77, 2004.
99. L. Hazlett and M. Wu, "Defensins in innate immunity," Cell and Tissue Research, vol. 343, pp. 175-188, 2011.
100. Q. Yuan and W. A. Walker, "Innate immunity of the gut: mucosal defense in health and disease," Journal of Pediatric Gastroenterology and Nutrition, vol. 38, no. 5, pp. 463-473, 2004.
101. T. Minami, H. Tojo, Y. Shinomura, Y. Matsuzawa, and M. Okamoto, "Increased group II phospholipase A2 in colonic mucosa of patients with Crohns disease and ulcerative colitis," Gut, vol. 35, no. 11, pp. 1593-1598, 1994.
102. S. Yamashita, M. Ogawa, T. Abe et al., "Group II phospholipase A2 in invasive gastric cancer cell line is induced by interleukin 6," Biochemical and Biophysical Research Communications, vol. 198, no. 3, pp. 878-884, 1994.
103. T. Ikegami, Y. Matsuzaki, J. Shoda, M. Kano, N. Hirabayashi, and N. Tanaka, "The chemopreventive role of ursodeoxycholic acid in azoxymethane-treated rats: suppressive effects on enhanced group II phospholipase A2 expression in colonic tissue," Cancer Letters, vol. 134, no. 2, pp. 129-139, 1998.
104. M. M. Haapamaki, J. M. Gronroos, H. Nurmi, K. Irjala, K. A. Alanen, and T. J. Nevalainen, "Phospholipase A2 in serumand colonicmucosa in ulcerative colitis," Scandinavian Journal of Clinical and Laboratory Investigation, vol. 59, no. 4, pp. 279-288, 1999.
105. M. M. Haapamaki, J. M. Gronroos, H. Nurmi, K. Alanen, M. Kallajoki, and T. J. Nevalainen, "Gene expression of group II phospholipase A2 in intestine in ulcerative colitis," Gut, vol. 40, no. 1, pp. 95-101, 1997.
106. T. J. Nevalainen, M. M. Haapamaki, and J. M. Gronroos, "Roles of secretory phospholipases A2 in inflammatory diseases and trauma," Biochimica et Biophysica Acta, vol. 1488, no. 1-2, pp. 83-90, 2000.
107. T. J. Nevalainen,G. G. Graham, and K. F. Scott, "Antibacterial actions of secreted phospholipases A2. Review," Biochimica et Biophysica Acta, vol. 1781, no. 1-2, pp. 1-9, 2008.
108. B. P. Kennedy, C. Soravia, J. Moffat et al., "Overexpression of the nonpancreatic secretory group II PLA2 messenger RNA and protein in colorectal adenomas from familial adenomatous polyposis patients," Cancer Research, vol. 58, no. 3, pp. 500-503, 1998.
109. L. Tribler, L. T. Jensen, K. Jorgensen et al., "Increased expression and activity of group IIA and X secretory phospholipase A2 in peritumoral versus central colon carcinoma tissue," Anticancer Research, vol. 27, no. 5, pp. 3179-3185, 2007.
110. T. Minami, Y. Shinomura, J. I. Miyagawa, H. Tojo, M. Okamoto, and Y. Matsuzawa, "Immunohistochemical localization of group II phospholipase A2 in colonic mucosa of patients with inflammatory bowel disease," American Journal of Gastroenterology, vol. 92, no. 2, pp. 289-292, 1997.
111. A. P. Femia, C. Luceri, S. Toti, A. Giannini, P. Dolara, and G. Caderni, "Gene expression profile and genomic alterations in colonic tumours induced by 1,2-dimethylhydrazine (DMH) in rats," BMC Cancer, vol. 10, article 194, 2010.
112. G. Zallen, E. E.Moore, J. L. Johnson et al., "New mechanisms by which secretory phospholipase A2 stimulates neutrophils to provoke the release of cytotoxic agents," Archives of Surgery, vol. 133, no. 11, pp. 1229-1233, 1998.
113. C. O. Bingham and K. Frank Austen, "Phospholipase A2 enzymes in eicosanoid generation," Proceedings of the Association of American Physicians, vol. 111, no. 6, pp. 516-524, 1999.
114. L. A. Marshall and D. W. Morgan, "Modulation of arachidonic acid metabolism: focus on phospholipase A2(s)," Drug News and Perspectives, vol. 11, no. 2, pp. 82-91, 1998.
115. N. Droin, J. B. Hendra, P. Ducoroy, and E. Solary, "Human defensins as cancer biomarkers and antitumour molecules," Journal of Proteomics, vol. 72, no. 6, pp. 918-927, 2009.
116. R. N. Cunliffe and Y. R. Mahida, "Antimicrobial peptides in innate intestinal host defence," Gut, vol. 47, no. 1, pp. 16-17, 2000.
117. S. Kanmura, H. Uto, M. Numata et al., "Human neutrophil peptides 1-3 are useful biomarkers in patients with active ulcerative colitis," Inflammatory Bowel Diseases, vol. 15, no. 6, pp. 909-917, 2009.
118. R. N. Cunliffe, M. Kamal, F. R. A. J. Rose, P. D. James, and Y. R. Mahida, "Expression of antimicrobial neutrophil defensins in epithelial cells of active inflammatory bowel disease mucosa," Journal of Clinical Pathology, vol. 55, no. 4, pp. 298-304, 2002.
119. M. Rodr?guez-Garc?a, H. Oliva, N. Climent, F. Garc?a, J. M. Gatell, and T. Gallart, "Human immature monocyte-derived dendritic cells produce and secrete α-defensins 1-3," Journal of Leukocyte Biology, vol. 82, no. 5, pp. 1143-1146, 2007.
120. H.Mothes, C.Melle, G. Ernst, R. Kaufmann, F. Von Eggeling, and U. Settmacher, "Human Neutrophil Peptides 1-3- early markers in development of colorectal adenomas and carcinomas," Disease Markers, vol. 25, no. 2, pp. 123-129, 2008.
121. J. Albrethsen, R. Bogebo, S. Gammeltoft, J.Olsen, B.Winther, and H. Raskov, "Upregulated expression of human neutrophil peptides 1,2 and 3 (HNP 1-3) in colon cancer serum and tumours: a biomarker study," BMC Cancer, vol. 5, article 8, 2005.
122. C. Melle, G. Ernst, B. Schimmel et al., "Discovery and identification of α-defensins as low abundant, tumor-derived serum markers in colorectal cancer," Gastroenterology, vol. 129, no. 1, pp. 66-73, 2005.
123. L. Sorokin, "The impact of the extracellular matrix on inflammation," Nature Reviews Immunology, vol. 10, no. 10, pp. 712-723, 2010.
124. H. Ohtani, "Stromal reaction in cancer tissue: pathophysiologic significance of the expression of matrix-degrading enzymes in relation to matrix turnover and immune/inflammatory reactions," Pathology International, vol. 48, no. 1, pp. 1-9, 1998.
125. D. L. Worthley, A. S. Giraud, and T. C. Wang, "The extracellular matrix in digestive cancer," Cancer Microenvironment, vol. 3, no. 1, pp. 177-185, 2010.
126. G. I. Abelev and N. L. Lazarevich, "Control of differentiation in progression of epithelial tumors," Advances in Cancer Research, vol. 95, pp. 61-113, 2006.
127. S. H. Kim, J. Turnbull, and S. Guimond, "Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor," Journal of Endocrinology, vol. 209, no. 2, pp. 139-151, 2011.
128. S. Groos, G. Hunefeld, and L. Luciano, "Epithelial cell turnover- extracellular matrix relationship in the small intestine of human adults," Italian Journal of Anatomy and Embryology, vol. 106, no. 2, pp. 353-361, 2001.
129. P. Simon-Assmann, M. Kedinger, and K. Haffen, "Immunocytochemical localization of extracellular-matrix proteins in relation to rat intestinal morphogenesis," Differentiation, vol. 32, no. 1, pp. 59-66, 1986.
130. D. Gagne, J. F. Groulx, Y. D. Benoit et al., "Integrinlinked kinase regulates migration and proliferation of human intestinal cells under a fibronectin-dependent mechanism," Journal of Cellular Physiology, vol. 222, no. 2, pp. 387-400, 2010.
131. S. Westcarr, P. Farshori, J. Wyche, and W. A. Anderson, "Apoptosis and differentiation in the crypt-villus unit of the rat small intestine," Journal of Submicroscopic Cytology and Pathology, vol. 31, no. 1, pp. 15-30, 1999.
132. P. H. Vachon, A. Simoneau, F. E. Herring-Gillam, and J. F. Beaulieu, "Cellular fibronectin expression is down-regulated at the mRNA level in differentiating human intestinal epithelial cells," Experimental Cell Research, vol. 216, no. 1, pp. 30-34, 1995.
133. A. M. DeGiorgio-Miller, L. J. Treharne, R. J. McAnulty, P. D. Coleridge Smith, G. J. Laurent, and S. E. Herrick, "Procollagen type I gene expression and cell proliferation are increased in lipodermatosclerosis," British Journal of Dermatology, vol. 152, no. 2, pp. 242-249, 2005.
134. D. Gradl, M. Kuhl, and D. Wedlich, "The Wnt/Wg signal transducer β-catenin controls fibronectin expression," Molecular and Cellular Biology, vol. 19, no. 8, pp. 5576-5587, 1999.
135. H. Takayasu, H. Horie, E. Hiyama et al., "Frequent deletions and mutations of the β-catenin gene are associated with overexpression of cyclin D1 and fibronectin and poorly differentiated histology in childhood hepatoblastoma," Clinical Cancer Research, vol. 7, no. 4, pp. 901-908, 2001.
136. V. L. Kolachala, R. Bajaj, L. Wang et al. Epithelial-derived fibronectin expression, signaling, and function in intestinal inflammation," Journal of Biological Chemistry, vol. 282 no. 45 pp. 32965-32973, 2007.
137. B. Walia, F. E. Castaneda, L. Wang et al., "Polarized fibronectin secretion induced by adenosine regulates bacterialepithelial interaction in human intestinal epithelial cells," Biochemical Journal, vol. 382, no. 2, pp. 589-596, 2004.
138. L. L. Graham, T. Friel, and R. L. Woodman, "Fibronectin enhances Campylobacter fetus interaction with extracellular matrix components and INT 407 cells," Canadian Journal of Microbiology, vol. 54, no. 1, pp. 37-47, 2008.
139. R. Isenmann, M. Schwarz, E. Rozdzinski et al., "Interaction of fibronectin and aggregation substance promotes adherence of Enterococcus faecalis to human colon," Digestive Diseases and Sciences, vol. 47, no. 2, pp. 462-468, 2002.
140. M. E. Konkel, J. E. Christensen, A. M. Keech, M. R. Monteville, J. D. Klena, and S. G. Garvis, "Identification of a fibronectin-binding domain within the Campylobacter jejuni CadF protein," Molecular Microbiology, vol. 57, no. 4, pp. 1022-1035, 2005.
141. P. Jaluria, K. Konstantopoulos, M. Betenbaugh, and J. Shiloach, "A perspective on microarrays: current applications, pitfalls, and potential uses," Microbial Cell Factories, vol. 6, article 4, 2007.
142. J. Terzic, S. Grivennikov, E. Karin, andM. Karin, "Inflammation and colon cancer," Gastroenterology, vol. 138, no. 6, pp. 2101-2114.e5, 2010.
143. J. E. Klaunig, Z. Wang, X. Pu, and S. Zhou, "Oxidative stress and oxidative damage in chemical carcinogenesis," Toxicology and Applied Pharmacology, vol. 254, no. 2, pp. 86-99, 2011.
144. L. B. Meira, J. M. Bugni, S. L. Green et al., "DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice," Journal of Clinical Investigation, vol. 118, no. 7, pp. 2516-2525, 2008.
145. F. V. N. Din, E. Theodoratou, S. M. Farrington et al., "Effect of aspirin and NSAIDs on risk and survival from colorectal cancer," Gut, vol. 59, no. 12, pp. 1670-1679, 2010.
146. R. E. Harris, "Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung," Inflammopharmacology, vol. 17, no. 2, pp. 55-67, 2009.
147. A. M. Abulafi and N. S. Williams, "Local recurrence of colorectal cancer: the problem, mechanisms, management and adjuvant therapy," British Journal of Surgery, vol. 81, no. 1, pp. 7-19, 1994.
148. T. Ushijima, "Epigenetic field for cancerization," Journal of Biochemistry and Molecular Biology, vol. 40, no. 2, pp. 142- 150, 2007.
149. B. J. M. Braakhuis,M. P. Tabor, J. A. Kummer, C. R. Leemans, and R. H. Brakenhoff, "A genetic explanation of slaughters concept of field cancerization: evidence and clinical implications," Cancer Research, vol. 63, no. 8, pp. 1727-1730, 2003.